Although Croatia follows the EU Transparency Directive, decision-making processes are often delayed, resulting in low availability of new medicines (28%) and long waiting times (almost 500 days). AmCham proposes reforms to ensure compliance with legal deadlines, improve transparency in pricing, establish clear criteria for therapeutic price referencing, and recognize the added therapeutic value of innovative medicines. Price control should apply only to drugs funded by public insurance, while others should be left to market competition. The goal is a more efficient system and better patient access to medicines.